OUR CLINICAL TRIALS

  • Reset


A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic Leer mas
Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, Leer mas
Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes. Leer mas
A window-of-opportunity study of U3-1402, a HER3-targeting antibody-drug conjugate in operable breast cancer according to Leer mas
A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Leer mas
Phase 0 multicenter, window of opportunity, three-arm, randomized clinical trial of oral metronomic vinorelbine and Leer mas
NiVOlumab for Luminal advanced/metastatic breast cancer to Taper ct-dnA In endocrine REsistance Leer mas
An open-label study of the effect of first-line Herceptin® alone or in combination with a Leer mas

COLLABORATE